European Commission Approves Empliciti Triple Combo for Advanced Multiple Myeloma
The European Commission (EC) has approved Empliciti (elotuzumab) in combination with Pomalyst (pomalidomide) and low-dose dexamethasone for the treatment…
Joana Carvalho, PhD, managing science editor — 
Articles by Joana Carvalho
CAR T-cell Therapy Combo Shows Promise in Treating Advanced Multiple Myeloma, Study Says
Using a combination of CAR T-cell therapies to target different cancer molecules appears to be a feasible and promising way of treating relapsed or refractory…
CHMP Favors Empliciti Triple Combo to Treat Advanced Multiple Myeloma Patients in EU
The Committee for Medicinal Products for Human Use (CHMP), a branch of the European Medicines Agency (EMA), has recommended that Empliciti (elotuzumab)…
Request for Darzalex as Faster and Easier Under-the-skin Infusion for Multiple Myeloma Before FDA
Janssen has asked the U.S. Food and Drug Administration (FDA) to approve a new subcutaneous (under-the-skin) formulation of Darzalex (daratumumab) as a…
FDA Approves Xpovio Combo for Heavily Treated RRMM Patients
The U.S. Food and Drug Administration (FDA) has approved — with conditions — Xpovio (selinexor) tablets, in combination with the corticosteroid…
Scientists Find ‘On/off Switch’ of Malignant MM Cancer Cells, May Lead to New Therapies, Study Says
Scientists discovered a set of genes that work as an “on/off switch” for malignant multiple myeloma cancer cells, which may shed light into new…
FDA Approves Darzalex-Revlimid-dexamethasone Combo to Treat Newly Diagnosed Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has approved Janssen‘s Darzalex (daratumumab), used in combination with Revlimid…
Selinexor Combo Yields Strong Responses in Difficult-to-treat Multiple Myeloma
Selinexor in combination with dexamethasone and Pomalyst (pomalidomide) leads to strong and durable anti-cancer responses, without significant side effects, in patients with…
CT103A CAR T-cell Therapy Leads to Strong Anti-cancer Responses in Relapsed or Refractory Multiple Myeloma Patients, Trial Shows
CT103A, a fully-human anti-B-cell mature antigen (BCMA) CAR T-cell therapy, leads to strong anti-cancer responses in patients with relapsed or refractory multiple…
Ygalo Continues to Induce Clinically Meaningful Responses in Relapsed or Refractory Multiple Myeloma, Phase 1/2 Trials Show
Ygalo (melflufen) combination therapy continues to lead to clinically meaningful responses, without significant side effects, in patients with relapsed or refractory multiple…